ISCT, International Society for Cell & Gene Therapy

As many of you know, the ISCT community is truly something special. Our global, expert-guided, and translation-focused community thrives because of our ISCT members. Our Annual Meetings are the epicentre of our community and a hub of connectivity uniting professionals from across academia, commercialization, regulatory and the clinic to advance the field and change the lives of patients worldwide. Whether you've attended one or thirty, you know an ISCT annual meeting, is the place to connect with peers and CGT leaders, discover the groundbreaking science of the future, and form connections and partnerships that will last a lifetime. To celebrate our 30th anniversary, we wanted to capture the essence of these meetings and the vibrant community that makes them possible. We are proud to present this special video from our ISCT 2024 Vancouver Annual Meeting, showcasing the unparalleled sense of community that defines ISCT. Join us in reliving these unforgettable moments and be reminded of why the ISCT community is like no other.

18-MONTH INDUSTRY MEMBERSHIP NOW AVAILABLE JOIN OUR GLOBAL, TRANSLATION-FOCUSED INDUSTRY COMMUNITY ISCT is excited to launch an 18-Month Industry Membership, spanning the remainder of 2024 until December 2025! This extended membership allows you to join ISCT’s exclusive Industry Community today and take advantage of our extensive list of member benefits until 2026. Discover who our current Industry Community Members are and the key benefits to your organization: https://buff.ly/4bHVON6 Contact us directly to learn more: Lydia Redmond, Administrator, Industry Program Management – lydia@isctglobal.org

ISCT along with the American Society of Transplantation (AST) and the Tissue Engineering and Regenerative Medicine International Society, Inc. (TERMIS) has co-organized a webinar series bringing together experts from the fields of transplant and regenerative medicine in order to share knowledge and foster progress in organ bioengineering, regeneration and repair. Join us on July 16 for the 18th installment of the series and hear from two esteemed leaders in regenerative medicine Dr. Andrea Banfi and Dr. Benjamin Freedman on the topic of Vasculature in Regenerative Medicine. Register now: https://buff.ly/462WRpF

Offer Ends July 12 – Take advantage of our early-bird discount on CGT Biomanufacturing Training Courses Whether you are in need of experiential hands-on lab training or seeking theoretical and practical applications of cell therapy bioprocessing and biomanufacturing, our courses are developed to support your training needs. Attend virtually anywhere in the world: https://buff.ly/48odEmK Receive expert-guided hands-on lab training: https://buff.ly/3u2Z4D9

ISCT joins 30+ organizations urging all of those involved in the new EU Joint Clinical Assessment (JCA) to recognize and use all types of available clinical evidence, including single-arm trials and real-world evidence, in the assessment of Advanced Therapy Medicinal Products (ATMPs), which include cell and gene therapies. By centralizing assessments currently made by each EU country in parallel, the Joint Clinical Assessment has the potential to accelerate patient access to new treatments. However, without methodologies appropriate to the development of ATMPs, the JCA could create a new barrier to these transformative therapies. The signatories of the Call to Action are committed to working together to mobilise efforts to bring these issues to the attention of the European Commission, the JCA Coordination Group and members at the national level. Read full press release: https://buff.ly/4bCbRfz #EUHealth; #EUHTA; #JCA

ISCT commends the recent verdict in a landmark class action lawsuit against the Lung Institute, a provider of unproven cell-based therapies for patients with lung diseases. Learn More: https://buff.ly/4cU94zq

ISCT is excited to announce Innovation Zone Presentations at ISCT Europe 2024! This exclusive platform is designed for disruptive cell and gene therapy \(CGT\) start-ups to showcase their groundbreaking technologies and elevate their corporate visibility. Selected applicants will receive a 10-minute presentation slot within the ISCT Europe Program, with the unique opportunity to receive direct feedback from a panel of industry experts including investors in the field. Apply now to claim one of our limited spaces! Applications close July 17, 2024. https://buff.ly/4eDCV0C

NEW ON-DEMAND COURSE NOW AVAILABLE - Advance your knowledge on MSCs for Autoimmune Diseases! Leveraging ISCT global network Leaders and Principal Investigators, including Katarina Le Blanc, MD, PhD, Mark Lowdell, PhD, Dominique Farge, MD, PhD, and Gary Gilkeson, MD, who have led significant studies in MSC research and clinical trials, The ISCT Institute of Training and Development has curated the Cell Therapies for Autoimmune Diseases: MSCs for Clinical Applications on-demand course. In this 8-hour case study-based ASCP accredited training course, learn from global leaders in the MSC field on the critical knowledge, methods, and considerations to apply when translating the use of MSC for autoimmune diseases. Learn more and register: https://buff.ly/4eSAOpJ

ISCT and the ISCT Committee on the Ethics of Cell and Gene Therapy (ECGT) are proud to announce the launch of the ISCT Healthcare Provider Guide to Unproven Cell and Gene Therapies, a critical tool and knowledge source for the cell and gene therapy sector. Access the guide now: https://buff.ly/3xvFhy4

Keen to revisit the cutting edge science from ISCT 2024 Vancouver? ISCT is pleased to announce that the recordings from the Translational Pathway Program are now available on demand to ISCT 2024 delegates. Access these valuable resources to stay at the forefront of the latest advancements in the field. https://buff.ly/4eLWlR4